Request a Quote

Cyprotex announces a collaborative research agreement with Pfizer

Cyprotex announces a collaborative research agreement with Pfizer

30 October 2012 - Cyprotex PLC (AIM:CRX), the preclinical ADME-Tox services company, today announces a collaborative research agreement between Apredica LLC (a wholly owned subsidiary of Cyprotex PLC) and Pfizer Inc. The deal extends over an eighteen month period and is split into two stages with the second stage being dependent on certain milestones being achieved. The collaboration is a research-based project which the parties aim to evaluate, further develop, and improve several of Cyprotex’s proprietary offerings in the area of predictive toxicology.

Dr. Anthony Baxter, Cyprotex’s Chief Executive Officer, comments on the collaboration: “We are delighted to be able to continue our relationship with Pfizer. This collaborative research is beneficial for both companies and allows Cyprotex to remain at the forefront of new approaches in toxicology prediction. Predicting drug-induced toxicity is a challenging field, and we are making significant advances by combining our knowledge with that of our partners and clients
 

For further information:

Cyprotex PLC Tel: +44 (0) 1625 505 100
Dr Anthony Baxter, Chief Executive Officer
John Dootson, Chief Financial Officer
Mark Warburton, Chief Operating Officer and Legal Counsel
ir@cyprotex.com
www.cyprotex.com

N+1 Singer (Nomad and broker to Cyprotex)
Tel: +44 (0)20 7496 3000
Shaun Dobson
Jenny Wyllie
shaun.dobson@nplus1singer.com
jenny.wyllie@nplus1singer.com
www.nplus1singer.com

FTI Consulting Tel: +44 (0) 20 7831 3113
Ben Brewerton
Simon Conway
Mo Noonan
cyprotex@fticonsulting.com
www.fticonsulting.com

Contact us

Archives

Close
Contact us to discuss your ADME Tox issues or request a quote

Telephone:
Europe: +44 (0)1625 505100
North America (East Coast): +1-888-297-7683

or fill out the form below:

Close
Close

Download file

Close